Japan approves Wegovy under a narrow obesity indication

Japan's Ministry of Health, Labour and Welfare (MHLW) approved Wegovy, the once-weekly semaglutide injection made by Novo Nordisk, for the treatment of obesity, according to a report published April 10, 2023 ^[1]. Wegovy contains the same active ingredient, semaglutide, found in the diabetes drugs Ozempic (injection) and Rybelsus (tablet) ^[1].

The approval is not a blanket clearance for weight loss. Under the terms described in the report, Wegovy can only be prescribed to patients who have hypertension, dyslipidemia, or type 2 diabetes and who have not responded adequately to diet and exercise therapy ^[1]. On top of that comorbidity requirement, patients must also meet one of two body mass index (BMI) thresholds: a BMI of at least 27 kg/m2 combined with at least two obesity-related health disorders, or a BMI of at least 35 kg/m2 on its own ^[1].

This structure means the drug's Japanese label ties eligibility to a specific set of related health conditions rather than to obesity or excess weight alone. A person with a high BMI but none of the listed conditions — hypertension, dyslipidemia, or type 2 diabetes — would not qualify under the criteria described in the approval ^[1].

The source does not specify a launch date, a list price in Japan, or details about insurance coverage for the drug once available ^[1]. Those details are not yet known from the available reporting.

Why it matters for patients

For people in Japan hoping to use Wegovy for weight management, the approval means access will likely be limited to those who already have a diagnosed weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes, plus a BMI that meets one of the two specified thresholds ^[1]. Patients who have obesity but do not have one of those three named conditions would not appear to meet the approved criteria as described ^[1].

The two-tiered BMI structure — a lower BMI threshold of 27 paired with multiple additional health disorders, or a higher BMI of 35 on its own — also means that doctors evaluating candidates will need to weigh both weight and the presence of other conditions before prescribing ^[1]. This narrower indication contrasts with a drug simply being available to anyone with obesity, and it puts more emphasis on documented comorbidities as part of the prescribing decision ^[1].

Because the source does not address pricing, insurance reimbursement, or timing of availability in pharmacies, patients in Japan will not yet know from this reporting how much the drug will cost or when they might realistically be able to obtain it ^[1].

What happens next

The report does not include a specific date for when Wegovy will become available to patients in Japan, nor does it describe reimbursement or pricing decisions ^[1]. Those steps are not yet known based on the available source material.